23 Sep Non–TNF-Targeted Biologic Found Superior to Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug
MedicalResearch.com Interview with:
Jacques-Eric Gottenberg, MD, PhD
Department of Rheumatology
National Reference Center for Systemic Autoimmune Diseases
Strasbourg University Hospital, Université de Strasbourg
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There is no recommendation for the choice of the second biologic in patients with rheumatoid arthritis and insufficient response to a first anti-TNF, which is a common situation in our daily practice (approximately one third of patients treated with anti-TNF). We therefore conducted the first randomized trial to date to investigate the best strategy in such a setting.
MedicalResearch.com: What should readers take away from your report?
Response: We demonstrated a superior effectiveness of non-TNF targeted biologics (abatacept, rituximab or tocilizumab) compared to a second anti-TNF medication.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Future research should now compare the non-TNF targeted biologic by implementing head to head randomized controlled trials (for example abatacept versus tocilizumab).
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Gottenberg J, Brocq O, Perdriger A, et al. Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. JAMA. 2016;316(11):1172-1180. doi:10.1001/jama.2016.13512.
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
More Medical Research Interviews on MedicalResearch.com
Last Updated on September 26, 2016 by Marie Benz MD FAAD